Yüklüyor......
Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B-cell lymphoma: A meta-analysis
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma (NHL), representing 30% of all lymphoma cases. Within the first 2-3 years following immunochemotherapy, 30-40% of patients will experience a relapse or a refractory disease, thereby exhibiting a poor prog...
Kaydedildi:
| Yayımlandı: | Mol Clin Oncol |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
D.A. Spandidos
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7416618/ https://ncbi.nlm.nih.gov/pubmed/32789017 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2020.2103 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|